Article

Daily Medication Pearl: Privigen Immune Globulin Intravenous (Human)

Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.

Medication Pearl of the Day: Privigen Immune Globulin Intravenous (Human)

Indication: Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.

Insight:

  • Dosing: Dosing may vary from 0.5 mg/kg/min to 8 mg/kg/min
  • Dosage forms: Privigen is a liquid solution containing 10% IgG (0.1 g/mL).
  • Adverse events: The most common adverse reactions, observed in >5% of study subjects, were headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.
  • Mechanism of action: Privigen supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The mechanism of action has not been fully elucidated but may include immunomodulatory effects.

Source: Privigen-Prescribing-Information.pdf (llnwd.net)

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards